Baba Kenta, Oshita Akihiko, Kohyama Mohei, Inoue Satoshi, Kuroo Yuta, Yamaguchi Takuro, Nakamura Hiroyuki, Sugiyama Yoichi, Tazaki Tatsuya, Sasaki Masaru, Imamura Yuji, Daimaru Yutaka, Ohdan Hideki, Nakamitsu Atsushi
Kenta Baba, Akihiko Oshita, Mohei Kohyama, Satoshi Inoue, Yuta Kuroo, Takuro Yamaguchi, Hiroyuki Nakamura, Yoichi Sugiyama, Tatsuya Tazaki, Masaru Sasaki, Yuji Imamura, Atsushi Nakamitsu, Department of Surgery, JA Hiroshima General Hospital, Hiroshima 738-8503, Japan.
World J Gastroenterol. 2015 Feb 14;21(6):1982-8. doi: 10.3748/wjg.v21.i6.1982.
A 72-year-old woman with a sigmoid colon cancer and a synchronous colorectal liver metastasis (CRLM), which involved the right hepatic vein (RHV) and the inferior vena cava (IVC), was referred to our hospital. The metastatic lesion was diagnosed as initially unresectable because of its invasion into the confluence of the RHV and IVC. After she had undergone laparoscopic sigmoidectomy for the original tumor, she consequently had 3 courses of modified 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus cetuximab. Computed tomography revealed a partial response, and the confluence of the RHV and IVC got free from cancer invasion. After 3 additional courses of mFOLFOX6 plus cetuximab, preoperative percutaneous transhepatic portal vein embolization (PTPE) was performed to secure the future remnant liver volume. Finally, a right hemihepatectomy was performed. The postoperative course was uneventful. The patient was discharged from the hospital on postoperative day 13. She had neither local recurrence nor distant metastasis 18 mo after the last surgical intervention. This multidisciplinary strategy, consisting of conversion chemotherapy using FOLFOX plus cetuximab and PTPE, could contribute in facilitating curative hepatic resection for initially unresectable CRLM.
一名72岁女性,患有乙状结肠癌并伴有同时性结直肠癌肝转移(CRLM),转移灶累及右肝静脉(RHV)和下腔静脉(IVC),被转诊至我院。由于转移灶侵犯RHV和IVC汇合处,最初诊断为不可切除。在她接受了针对原发肿瘤的腹腔镜乙状结肠切除术后,接受了3个疗程的改良氟尿嘧啶、亚叶酸钙和奥沙利铂(mFOLFOX6)联合西妥昔单抗治疗。计算机断层扫描显示部分缓解,RHV和IVC汇合处无癌侵犯。在追加3个疗程的mFOLFOX6联合西妥昔单抗治疗后,进行了术前经皮经肝门静脉栓塞术(PTPE)以确保未来残余肝体积。最后,进行了右半肝切除术。术后过程顺利。患者于术后第13天出院。在最后一次手术干预后18个月,她既无局部复发也无远处转移。这种由使用FOLFOX联合西妥昔单抗的转化化疗和PTPE组成的多学科策略,有助于促进对最初不可切除的CRLM进行根治性肝切除。